Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
6322581
Reference Type
Journal Article
Subtype
Review
Title
Male breast cancer: a disease distinct from female breast cancer
Author(s)
Gucalp, A; Traina, TA; Eisner, JR; Parker, JS; Selitsky, SR; Park, BH; Elias, AD; Baskin-Bey, ES; Cardoso, F
Year
2019
Is Peer Reviewed?
Yes
Journal
Breast Cancer Research and Treatment
ISSN:
0167-6806
EISSN:
1573-7217
Volume
173
Issue
1
Page Numbers
37-48
Language
English
PMID
30267249
DOI
10.1007/s10549-018-4921-9
Web of Science Id
WOS:000459448500005
Abstract
PURPOSE:
Male breast cancer (BC) is rare, representing approximately 1% of cancers that occur in men and approximately 1% of all BCs worldwide. Because male BC is rare, not much is known about the disease, and treatment recommendations are typically extrapolated from data available from clinical trials enrolling female BC patients.
METHODS:
We review the epidemiology, risk factors, prognosis, and the varied molecular and clinicopathologic features that characterize male BC. In addition, we summarize the available data for the use of systemic therapy in the treatment of male BC and explore the ongoing development of targeted therapeutic agents for the treatment of this subgroup of BCs.
RESULTS:
There are important biological differences between male and female BC. Male BC is almost exclusively hormone receptor positive (+), including the androgen receptor (AR), and is associated with an increased prevalence of BRCA2 germline mutations, especially in men with increased risk for developing high-risk BC. Additional research is warranted to better characterize male BC. To accomplish this, a multi-national consortium approach, such as the International Male Breast Cancer Program, is needed in response to the scarcity of patients. This approach allows the pooling of information from a large number of men with BC and the creation of registries for future therapeutic-focused clinical trials.
CONCLUSIONS:
Given the unique biology of BC in men, promising new therapeutic targets are currently under investigation, including the use of poly-ADP-ribose polymerase inhibitors or AR-targeted agents either as monotherapy or in combination with other agents.
Tags
PFAS
•
Additional PFAS (formerly XAgency)
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity